Core Viewpoint - Runmed-B (02297) experienced a significant decline of 10.0% in stock price, trading at 0.45 HKD per share as of 14:25 on August 20, with a transaction volume of 17.5763 million HKD [1] Company Overview - Runmed Medical Co., Ltd. aims to become a global leader in vascular interventional surgical robots, with key products including the caFFR system, caIMR system, and FlashBot vascular interventional surgical robot [1] - The company has established a global R&D, production, sales, and service network, collaborating with top medical centers and implementing a strict quality inspection system [1] - Runmed has successfully obtained certification for its medical device quality management system [1] Financial Performance - As of the 2024 annual report, Runmed-B reported total operating revenue of 39.824 million HKD and a net loss of 113 million HKD [2]

Core Viewpoint - Runmed-B (02297) experienced a significant intraday increase of 32.43%, reaching a price of 0.49 HKD per share with a trading volume of 18.92 million HKD [1]. Group 1: Company Overview - Runmed Medical Co., Ltd. aims to become a global leader in vascular interventional surgical robots, with key products including the caFFR system, caIMR system, and FlashBot vascular interventional surgical robot [1]. - The company has established a global network for research and development, production, sales, and service, collaborating with top medical centers and implementing a strict quality inspection system [1]. - Runmed has successfully obtained certification for its medical device quality management system [1]. Group 2: Financial Performance - As of the 2024 annual report, Runmed-B reported total operating revenue of 39.824 million HKD and a net profit of -113 million HKD [2].

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性或完整性亦不發表任 何聲明，並明確表示，概不就因本公告的全部或任何部份內容而產生或因倚賴該等內容而引致的任何損失承擔任何責 任。 Rainmed Medical Limited 潤邁德醫療有限公司 （於開曼群島註冊成立的有限公司） （股份代號：2297） 董事會會議召開日期 潤邁德醫療有限公司（「本公司」）董事會（「董事會」）謹此宣佈，本公司將於二零二五年八 月二十八日（星期四）舉行董事會會議，藉以(其中包括)考慮並批准本公司及其附屬公司截 至二零二五年六月三十日止六個月之未經審計的中期業績及其刊發，並考慮派發中期股息 (如有)，以及處理其他事項。 承董事會命 潤邁德醫療有限公司 董事會主席兼執行董事 霍雲飛 香港，二零二五年八月十八日 於本公告日期，董事會由執行董事霍雲飛先生、朱則柯先生及段靜女士；非執行董事霍雲龍博士、王霖先生及衡磊先 生；及獨立非執行董事廖船江先生丶陳雪峰先生及趙暉先生組成。 ...

Group 1 - Shenzhen Tongchuang Weiye Asset Management Co., Ltd. reduced its stake in Runmind Technology-B (02297) by 13 million shares at a price of HKD 0.3448 per share, totaling HKD 4.4824 million [1] - After the reduction, the latest shareholding number is 67.921 million shares, representing a holding percentage of 4.85% [1] - The transaction involved other related parties: Shenzhen Tongchuang Weiye Venture Capital Co., Ltd. and Huang Li [1]

Group 1 - Shenzhen Tongchuang Weiye Asset Management Co., Ltd. reduced its holdings in Runmind-B (02297) by 13 million shares at a price of HKD 0.3448 per share, totaling HKD 4.4824 million [1] - After the reduction, the latest number of shares held is 67.921 million, representing a holding percentage of 4.85% [1] - The transaction involved other related parties: Shenzhen Tongchuang Weiye Venture Capital Co., Ltd. and Huang Li [1]

Core Insights - Recent shareholder equity disclosures were made by several companies including Heptagon Pharmaceuticals-B, Ligao Holdings, Runmed-B, Aigo Group, and Hengxin Holdings on August 18, 2025 [1] Shareholder Changes - Heptagon Pharmaceuticals-B (02142): Golden Sage reduced its holdings from 62.985 million shares to 41.985 million shares, now holding 4.95% [2] - Ligao Holdings (08472): He Hanyu decreased its holdings from 9.034 million shares to 5.684 million shares, now holding 4.93% [2] - Runmed-B (02297): Huang Li reduced its holdings from 80.921 million shares to 67.921 million shares, now holding 4.85% [2] - Aigo Group (00328): Yu Jianchu acquired 5.746 million shares, now holding 5.02% [2] - Hengxin Holdings (01920): Ye Mingshen completely divested from 195 million shares, now holding 0% [2]

智通财经APP获悉，财讯传媒(00205)、立高控股(08472)、润迈德-B(02297)于2025年8月11日进行了最新 股东权益披露。 备注：持股数变动有可能因供股、合股、拆股等情况引起，请注意对照实际情况进行辨别。 | 股票名称 | 机构名称 | 性质 | 变动前持股 | 变动后持股 | 持股比 | | --- | --- | --- | --- | --- | --- | | 财讯传媒(00205) | YONG RONG (HK) ASSET MANAGEMENT | 好仓 | 1.37 亿股 | 1.97 亿股 | 17.84%(最新) 18.60%(前次) | | | LIMITED | | | | | | 立高控股(08472) | 叶永春 | 好仓 | 1011.45 万股 | 561.45 万股 | 4.87%(最新) 8.78%(前次) | | 润迈德-B(02297) | 深圳市同创伟业创业 | 好仓 | 9602.50 万股 | 8092.10 万股 | 5.77%(最新) | | | 投资有限公司 | | | | 6.85%(前次) | | 润迈德-B(02297) | 黄荔 | ...

香港联交所最新资料显示，8月1日，吕永辉减持润迈德-B(02297)79.5万股，每股作价0.3711港元，总金 额约为29.50万港元。减持后最新持股数目为3129.2万股，最新持股比例为2.23%。 ...

香港联交所最新资料显示，8月1日，吕永辉减持润迈德-B(02297)79.5万股，每股作价0.3711港元，总金 额约为29.50万港元。减持后最新持股数目为3129.2万股，最新持股比例为2.23%。 ...

股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年7月31日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 潤邁德醫療有限公司 呈交日期: 2025年8月4日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 02297 | 說明 | | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | | 法定/註冊股本 | | | 上月底結存 | | | 3,800,000,000 | HKD | | 0.0001 | HKD | | 380,000 | | 增加 / 減少 (-) | | | | | | | HKD | | | | 本月底結存 | | | 3,800,000,000 | HKD | | 0.0001 | HKD | | 380,000 | 本月底法定/註冊股本總額： ...